Physician profile
David Satinsky
NPI 1518939768
$906.31
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $244.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $216.63 | 2019 | |
| Amgen INC. | $69.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $67.06 | 2019 | |
| Genzyme Corporation | $66.10 | 2019 | |
| Biogen, INC. | $60.90 | 2019 | |
| Merz North America, INC. | $35.74 | 2019 | |
| Adamas Pharmaceuticals, INC. | $33.28 | 2019 | |
| Emd Serono, INC. | $27.55 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.27 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.44 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.17 | 2019 | |
| Ucb, INC. | $16.00 | 2019 | |
| Acorda Therapeutics, INC | $13.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Satinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.